{
    "nctId": "NCT00095862",
    "briefTitle": "Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers",
    "officialTitle": "A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Safety, tolerability, and feasibility",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer meeting 1 of the following criteria:\n\n  * Recurrent and/or metastatic lesions that are HER2/neu-positive or negative\n  * Recurrent or progressive cancer of the lung, ovary, pancreas, prostate, bladder, or other primary site associated with HER2/neu-positive tumor by histochemistry\n* Bone-only metastatic breast cancer, cytologically confirmed malignant effusions, histologically confirmed marrow involvement, or other evaluable (but non-measurable) metastatic disease allowed\n* Failed prior first-line chemotherapy (e.g., anthracycline- or taxane-based therapy) with or without adjuvant chemotherapy or hormonal therapy\n* No curative or reliably effective palliative surgery, radiotherapy, or medical therapy available\n* Stable brain metastases allowed provided the following criteria are met\\*:\n\n  * Previously treated\n  * No concurrent requirement for corticosteroids\n  * No radiological or clinical deterioration within the past 6 weeks NOTE: \\*Patients who had recent treatment with gamma knife or intensity-modulated radiotherapy for brain metastases are eligible provided there has been recovery from known or anticipated toxic effects\n* Patients with no HLA-A2 allele are eligible\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female or male\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 4 months\n\nHematopoietic\n\n* Absolute granulocyte count \u2265 1,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin \u2264 2 mg/dL\n* Alkaline phosphatase \u2264 5 times upper limit of normal (ULN)\n* ALT and AST \u2264 2 times ULN\n\nRenal\n\n* BUN \u2264 30 mg/dL\n* Creatinine \u2264 2 mg/dL\n* \u2264 1 g protein on 24-hour urine collection OR\n* \u2264 1+ proteinuria on urinalysis\n\nCardiovascular\n\n* Hypertension controlled by agents (except beta-blockers) allowed\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* HIV negative\n* No history of anaphylactic reaction to any known or unknown antigen\n* No history of clinical hypersensitivity to sargramostim (GM-CSF), interferon, yeast, beef, or to any components used in preparation of study vaccine\n* No clinical or laboratory features indicative of AIDS\n* No rheumatological, psychiatric, or other clinically progressive major medical problems requiring treatment\n* No other malignancy within the past 2 years\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* More than 3 weeks since prior biological therapy, including trastuzumab (Herceptin\\^\u00ae)\n* More than 3 weeks since prior immunotherapy\n* No concurrent immunotherapy\n\nChemotherapy\n\n* See Disease Characteristics\n* More than 3 weeks since prior chemotherapy (8 weeks for nitrosoureas or mitomycin)\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* See Disease Characteristics\n* More than 3 weeks since prior hormonal therapy\n* No concurrent hormonal therapy\n* No concurrent systemic steroids\n\n  * Concurrent inhalation steroids for respiratory hypersensitivity (e.g., triamcinolone nasal or pulmonary inhalers) allowed\n\nRadiotherapy\n\n* See Disease Characteristics\n* More than 3 weeks since prior radiotherapy\n* No concurrent radiotherapy\n\nSurgery\n\n* More than 3 weeks since prior major surgery with general anesthesia\n* No concurrent major surgery\n\nOther\n\n* Recovered from prior therapy\n* Patients receiving pamidronate, bisphosphonates, or other supportive measures must continue therapy during study participation\n* No concurrent anticoagulants\n* No concurrent beta-blockers for control of mild hypertension or other indications",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}